Back to Sites Byramjee Jeejeebhoy Medical College (BJMC) CRS Site Number 31441 Address BJ Medical College CRS Jai Prakash Narayan Road Pune, Maharashtra, 411001 India IMPAACT Members at this Site Ramesh Bhosale Co-Investigator Nikhil Gupte Co-Investigator Aarti Kinikar Co-Investigator Sandesh Patil Co-Investigator Nishi Suryavanshi CRS Coordinator Vidya Mave CRS Leader Ruth Harley CTU Coordinator Charles Flexner CTU Principal Investigator Amita Gupta CTU Principal Investigator Lynnea Roth DAIDS PO Sameer Khan Data Management Staff Navnath Jadhav Pediatrician Mandar Paradkar Pediatrician Monali Inamake Pharmacist Aarti Nagargoje Pharmacist Sadaf Inamdar Pharmacist of Record Nikhil Patil QA/QC Coordinator Pranali Kulal Regulatory Coordinator Anuradha Munagala Regulatory Coordinator Smita Nimkar Regulatory Coordinator Studies at this Site P1060: NNRTI-Based vs. PI-Based ART in Infants Exposed/Not Exposed to NVP for PMTCT DAIDS Number 10166 Research Area Treatment Study Status Concluded P1070: EFV in HIV-infected and HIV/TB Co-infected Subjects DAIDS Number 10633 Research Area Treatment Study Status Concluded P1073: Study of Immune Reconstitution Inflammatory Syndrome (IRIS) for International Sites Initiating Highly Active Antiretroviral Therapy (HAART) in Infants and Children <72 Months of Age DAIDS Number 10655 Research Area Other Study Status Concluded P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis 1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed 1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Enrolling IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
P1060: NNRTI-Based vs. PI-Based ART in Infants Exposed/Not Exposed to NVP for PMTCT DAIDS Number 10166 Research Area Treatment Study Status Concluded
P1070: EFV in HIV-infected and HIV/TB Co-infected Subjects DAIDS Number 10633 Research Area Treatment Study Status Concluded
P1073: Study of Immune Reconstitution Inflammatory Syndrome (IRIS) for International Sites Initiating Highly Active Antiretroviral Therapy (HAART) in Infants and Children <72 Months of Age DAIDS Number 10655 Research Area Other Study Status Concluded
P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis
1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed
1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) in Children with MDR-TB with and without HIV DAIDS Number 20721 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Enrolling
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling